amfAR Target Grants / ARCHE (HIV Cure)

amfAR, The Foundation for AIDS Research · Nonprofit

Source: amfAR, The Foundation for AIDS Research (curated) · View original posting ↗

Current RFP has SHIFTED TOPIC (verified 2026-07-30): the open Target Grants call is 'Therapeutic Immune Reprogramming in Cancer: Targeting Dysfunctional, Suppressive, and Senescent Immune States', performance period November 1, 2026 - October 31, 2028, up to $480,000 including up to 20% indirect costs. amfAR Target Grants rotate topic by cycle, so an HIV-cure round may return; this row is tagged for both verticals.

AwardWhat a single award can be worth — the funder's published per-award amount or floor–ceiling range.

Up to $480K

DeadlineFinal application due date.

Not yet posted

Letter of intentDue date for the letter of intent (a short pre-application some funders require or request before the full proposal).

—

MechanismNIH activity code — the grant type (R01 research project, R21 exploratory, K series career development, F series fellowship, …).

—

DurationMaximum project period for a single award.

2 yr

Expected awardsHow many awards the funder anticipates making under this opportunity.

—

Funding cycleHow often the program accepts applications (annual, multiple cycles per year, rolling, or one-time).

Recurring (annual)

Open dateWhen applications open (or opened).

—

Total fundingThe overall pool the funder expects to commit across ALL awards under this opportunity — not what one project receives.

$480K total

Clinical trialWhether proposed projects must, may, or must not include a clinical trial.

Optional / allowed